US FDA approves first drug for fatty liver disease NASH
THE US Food and Drug Administration (FDA) has approved Madrigal Pharmaceuticals’ drug for a fatty liver disease known as non-alcoholic steatohepatitis, or...
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharmaceutical manufacturing plant in Singapore. The expanded site will focus on...
AstraZeneca to buy Amolyt Pharma for US$1.05 billion to boost rare-disease portfolio
DRUGMAKER AstraZeneca said on Thursday (Mar 14) it would acquire rare endocrine diseases-focused firm Amolyt Pharma for US$1.05 billion in cash, in...
US FDA approves Novo Nordisk's Wegovy for lowering heart risks
THE US Food and Drug Administration approved Novo Nordisk’s weight-loss drug Wegovy on Friday (Mar 8) for lowering the risk of stroke...
Lilly Alzheimer drug faces more delays as FDA plans hearing
ELI Lilly’s Alzheimer’s disease drug donanemab faces further delays in gaining approval, with US regulators planning to hold a hearing of external...
Novo Nordisk confident of amycretin obesity drug launch this decade
NOVO Nordisk’s head of development on Friday (Mar 8) told Reuters he was very comfortable the drugmaker would be able to launch...
Ozempic is transforming the health of Denmark’s economy
FROM both a biomedical and economic point of view, the success of the new class of weight-loss drugs is something to behold.
Pfizer inflammatory bowel disease drug wins EU approval
PFIZER’S drug to treat patients with an inflammatory bowel disease called ulcerative colitis has been approved by the European Commission, the company...
Lilly’s climb has analysts asking US$1 trillion question
ELI Lilly & Co’s relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of...
AstraZeneca targets 2024 growth as portfolio booms
ASTRAZENECA expects to boost revenue and profit this year on the back of resilient demand for its cancer and rare disease drugs...